HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Screen & Chart at the same time

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Lyell Immunopharma, Inc

Contributing Author

Recent Articles by Lyell Immunopharma, Inc

May-12
Lyell Immunopharma Announces Participation in May Investor Conferences LYEL GlobeNewswire
May-06
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 LYEL GlobeNewswire
Apr-07
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference LYEL GlobeNewswire
Mar-12
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results LYEL -14.23% LYEL GlobeNewswire
Mar-09
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer LYEL +13.54% GlobeNewswire
Feb-23
Lyell Immunopharma Announces Participation in March Investor Conferences LYEL +6.12% GlobeNewswire
Feb-12
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma LYEL GlobeNewswire
Dec-07
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition LYEL GlobeNewswire
Nov-12
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 LYEL GlobeNewswire
Nov-10
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer LYEL GlobeNewswire
Nov-03
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition LYEL GlobeNewswire
Sep-03
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee LYEL GlobeNewswire
Sep-02
Lyell Immunopharma Announces Participation in September Investor Conferences LYEL GlobeNewswire
Aug-12
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025 LYEL GlobeNewswire
Jul-25
Lyell Immunopharma Announces up to $100 Million Equity Private Placement LYEL +19.31% GlobeNewswire
Jun-23
Lyell Immunopharma to Participate in the H.C. Wainwright "HCW@Home" Series LYEL +6.62% LYEL GlobeNewswire
Jun-17
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma LYEL GlobeNewswire
Jun-09
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments LYEL -13.39% LYEL GlobeNewswire
Jun-04
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference LYEL +68.59% LYEL -14.92% GlobeNewswire
May-13
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025 LYEL GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)